Arbutus reports FY2022 net loss $69.5M, cash runway into Q4 2024; pipeline milestones set for 2023

Arbutus Biopharma Corp

Net loss $69.5M ($0.46/share) vs $88.4M in 2021; revenue $39M up from $11M on Qilu license.
Cash $184.3M; expects net cash burn $95-100M in 2023, runway into Q4 2024.
AB-729 Phase 2a data with IFN expected H1 2023; trial with VTP-300 + nivolumab amended.
Phase 1 trials for oral PD-L1 AB-101 and RNA destabilizer AB-161 to start H1 2023; data H2 2023.
AB-343 (M pro inhibitor) Phase 1 expected H2 2023; discontinued AB-729+vebicorvir trial.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arbutus Biopharma Corp reported financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 2, 2023, Arbutus Biopharma Corporation (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022 and certain other information.

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

Arbutus Biopharma Corp filing history →

Source: SEC EDGAR

accession 0001171843-23-001339

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.